Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peretinoin (NIK-333) vs placebo for prevention of HCV-positive hepatocellular carcinoma recurrence
jRCT2080221786Phase 3Completed
- Sponsor
- Kowa Company, Ltd.
- Start
- May 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) and hepatitis C virus infection comparing Peretinoin 600 mg/day with Placebo (2 arms). Started May 2012; status: completed.
02
Drugs
peretinoin
03
Conditions
hepatocellular carcinoma (HCC)hepatitis C virus infection
Beyond the preview
Go deeper on jRCT2080221786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221786.